Karyopharm Therapeutics Inc.

Medical Science Liaison (MSL) – Launch Preparation

Job Locations US-Remote
Job ID
2026-2403
# of Openings
1
Category
Medical Affairs/HEOR
Type
Regular Full-Time

Role Overview & Key Functions:

As we prepare for potential upcoming launches, Karyopharm is seeking to connect with experienced Medical Science Liaisons across the United States. Medical Science Liaisons at Karyopharm serve as trusted scientific partners to the medical community, engaging thought leaders and healthcare professionals across hematologic malignancies and solid tumors. Areas of focus may include multiple myeloma, myelofibrosis, endometrial cancer, and select rare diseases aligned with near-term launch readiness and longer-term pipeline development.

 

RESPONSIBILITIES:

  • Identify, develop, and maintain relationships with community and academic thought leaders at the local, regional, and national level.
  • Serve as Karyopharm’s scientific representative, facilitating the appropriate exchange of scientific and clinical information.
  • Provide clinical and health-economic information to payers and managed care stakeholders, as appropriate.
  • Utilize approved resources in compliance with FDA, OIG, HIPAA, and company guidelines.
  • Partner with Clinical Operations to support trial awareness, enrollment, and identification of potential investigators or sites.
  • Support investigator-sponsored research activities.
  • Communicate therapeutic insights and market trends that may impact Karyopharm’s medical and pipeline strategy.
  • Participate in advisory boards, steering committees, and cross-functional project teams.
  • Contribute to MSL best practices and support team development as roles mature.

Candidate Profile & Requirements:

  • Advanced doctoral degree preferred (e.g. PharmD, MD, DO, or PhD). Candidates with a clinical background (e.g. MSN, PA) and extensive hematology/oncology MSL experience will be considered.
  • Minimum of 3 years of MSL experience in hematology, oncology, and/or select rare diseases required.
  • Experience in multiple myeloma, myelofibrosis, or gynecologic oncology strongly preferred.
  • Product launch experience a plus.
  • Clinical experience beneficial.
  • Exceptional interpersonal skills.
  • Ability to excel in dynamic settings with short timelines.
  • Strong written/verbal communication and presentation skills.
  • Ability to establish and maintain relationships with influential thought leaders.
  • Thorough understanding of FDA, OIG, HIPAA and other ethical guidelines, laws, and regulations relevant to the pharmaceutical industry.
  • Valid driver's license and the ability to travel as necessary (up to 75% including some weekends).

 

At Karyopharm, base pay is one part of a competitive total rewards package that includes comprehensive benefits (medical, dental, vision, 401(k), and more), equity and the potential to receive annual target bonuses. Actual pay is based on factors such as location, experience, skills, education, and internal equity. We maintain broad salary ranges to reflect market conditions and the specialized nature of our work. The anticipated base salary range for this position is $180 K - $215 K USD.

Our Value Proposition:

This is a uniquely exciting time to join Karyopharm Therapeutics where we are pioneering the science of nuclear export inhibition to develop differentiated therapies for patients with cancer. We are building upon an established commercial foundation in multiple myeloma while advancing the potential of selinexor across additional hematologic and solid tumor cancers including myelofibrosis and TP53 wild-type endometrial cancer, areas where patients continue to face significant unmet needs. 

 

Our lead therapy, XPOVIO® (selinexor), is a first-in-class inhibitor of exportin 1 (XPO1) and is approved in the U.S. for adults with relapsed or refractory multiple myeloma, with approvals in more than 50 countries and territories outside the U.S. We are also exploring opportunities to evaluate XPO1 inhibition across myeloproliferative neoplasms and TP53 wild-type driven solid tumors using next-generation compounds, including eltanexor.  

 

As we prepare for our next phase of growth, we are continuing to invest in critical capabilities across the organization to support future opportunities and deepen our impact in oncology. We are looking for talented people who are motivated by meaningful work, energized by growth and momentum, and excited by the opportunity to help shape what comes next in a collaborative, fast-moving environment where individual contributions are visible and valued. 

 

Learn more at Karyopharm Therapeutics. 

Options

Sorry the Share function is not working properly at this moment. Please refresh the page and try again later.
Share on your newsfeed